Related Experiment Video
Updated: Feb 26, 2026
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
Analysis of Drug Resistance Using Kinome-Wide Functional Screens
Katherine R Singleton1, Keith T Earley1, Lynn E Heasley2
1Department of Craniofacial Biology, University of Colorado Anschutz Medical Campus, 12801 E. 17th Ave., MS-8120, Aurora, CO, 80045, USA.
Abstract:
The clinical success of tyrosine kinase inhibitors specific for BCR-ABL-, EGFR-, ALK-, and ROS1-driven cancers continues to spur the quest to match specific oncogene-defined tumor types with an appropriate molecularly targeted therapy. Unfortunately, responses to these agents are not durable with intrinsic or acquired resistance limiting benefit. Additionally, efforts to identify the appropriate targets of new drugs have focused on nonfunctional assays such as large-scale sequencing for somatic mutations or analysis of gene copy number. Acknowledging both the problem of resistance and the shortcomings of the current methods for detecting appropriate drug targets, much interest has been focused on RNAi-based screens. These screens utilize a library of shRNAs targeting the whole genome or a subset of genes and provide a high-throughput and unbiased means to functionally assess genes impacting various aspects of tumor biology, especially proliferation and survival. The function of genes can be measured in the context of a specific drug treatment, termed a synthetic lethal screen, or genes may be assessed for their individual dependency, termed an essential gene screen. Here, we describe a method for performing both of these types of screens using a kinome-targeted shRNA library in human cancer cell lines.
Insights
This study introduces a new RNA interference (RNAi) screening method to identify drug targets in cancer. This approach addresses resistance to targeted therapies by functionally assessing gene dependencies.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Targeted therapies like tyrosine kinase inhibitors show clinical success in specific cancers but face challenges with resistance.
- Current methods for identifying drug targets, such as sequencing, are nonfunctional and do not fully address resistance mechanisms.
- RNA interference (RNAi)-based screens offer a high-throughput, unbiased approach to functionally assess genes in cancer biology.
Purpose of the Study:
- To develop and describe a novel method for performing RNAi-based screens in cancer cell lines.
- To enable the functional assessment of genes impacting tumor proliferation and survival in the context of drug treatment.
- To facilitate both synthetic lethal and essential gene screens using a kinome-targeted shRNA library.
Main Methods:
- Utilized a kinome-targeted short hairpin RNA (shRNA) library for genome-wide or subset screening.
- Employed RNA interference (RNAi) to functionally assess gene dependencies in human cancer cell lines.
- Designed the method to support both synthetic lethal screens (in the presence of drug) and essential gene screens (individual gene dependency).
Main Results:
- The described method allows for high-throughput, functional screening of genes.
- It enables the identification of genes critical for cancer cell proliferation and survival.
- The approach is applicable to both synthetic lethal and essential gene screening paradigms.
Conclusions:
- RNAi-based screening offers a powerful functional approach to overcome limitations of current target identification methods.
- This method can help identify novel therapeutic targets and understand resistance mechanisms in cancer.
- The described kinome-targeted shRNA screening platform provides a versatile tool for cancer research and drug discovery.
More Related Videos
Related Concept Videos
02:46Genetic Screens
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which...
02:56Treatment Resistant Cancers